Cargando…

Fluctuations in Parkinson’s disease and personalized medicine: bridging the gap with the neuropsychiatric fluctuation scale

BACKGROUND: Neuropsychiatric fluctuations (NpsyF) are frequent and disabling in people with Parkinson’s disease (PD). In OFF-medication, NpsyF entail minus neuropsychiatric symptoms (NPS) like anxiety, apathy, sadness, and fatigue. In ON-medication, NpsyF consist in plus NPS, such as high mood, hypo...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmitt, Emmanuelle, Debu, Bettina, Castrioto, Anna, Kistner, Andrea, Fraix, Valerie, Bouvard, Martine, Moro, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469620/
https://www.ncbi.nlm.nih.gov/pubmed/37662035
http://dx.doi.org/10.3389/fneur.2023.1242484
_version_ 1785099481947045888
author Schmitt, Emmanuelle
Debu, Bettina
Castrioto, Anna
Kistner, Andrea
Fraix, Valerie
Bouvard, Martine
Moro, Elena
author_facet Schmitt, Emmanuelle
Debu, Bettina
Castrioto, Anna
Kistner, Andrea
Fraix, Valerie
Bouvard, Martine
Moro, Elena
author_sort Schmitt, Emmanuelle
collection PubMed
description BACKGROUND: Neuropsychiatric fluctuations (NpsyF) are frequent and disabling in people with Parkinson’s disease (PD). In OFF-medication, NpsyF entail minus neuropsychiatric symptoms (NPS) like anxiety, apathy, sadness, and fatigue. In ON-medication, NpsyF consist in plus NPS, such as high mood, hypomania, and hyperactivity. Accurate identification of these NpsyF is essential to optimize the overall PD management. Due to lack of punctual scales, the neuropsychiatric fluctuation scale (NFS) has been recently designed to assess NpsyF in real time. The NFS comprises 20 items with two subscores for plus and minus NPS, and a total score. OBJECTIVE: To evaluate the psychometric properties of the NFS in PD. METHODS: PD patients with motor fluctuations and healthy controls (HC) were assessed. In PD patients, the NFS was administrated in both the ON-and OFF-medication conditions, together with the movement disorders society-unified Parkinson disease rating scale parts I–IV. Depression (Beck depression scale II), apathy (Starkstein apathy scale) and non-motor fluctuations items of the Ardouin scale of behaviour in PD (ASBPD OFF and ON items) were also assessed. NFS internal structure was evaluated with principal component analysis consistency (PCA) in both medication conditions in PD patients and before emotional induction in HC. NFS internal consistency was assessed using Cronbach’s alpha coefficient. NFS convergent and divergent validity was measured through correlations with BDI-II, Starktein, and ASBPD OFF and ON non motor items. Specificity was assessed comparing NFS global score between the HC and PD populations. Sensitivity was evaluated with t-student test comparing the ON-and the OFF-medication conditions for NFS global score and for minus and plus subscores. RESULTS: In total, 101 consecutive PD patients and 181 HC were included. In PD patients and HC, PCA highlighted one component that explained 32–35 and 42% of the variance, respectively. Internal consistency was good for both the NFS-plus (alpha =0.88) and NFS-minus items (alpha =0.8). The NFS showed a good specifity for PD (p < 0.0001) and a good sensitivity to the medication condition (p < 0.0001). CONCLUSION: The satisfactory properties of the NFS support its use to assess acute neuropsychiatric fluctuations in PD patients, adding to available tools.
format Online
Article
Text
id pubmed-10469620
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104696202023-09-01 Fluctuations in Parkinson’s disease and personalized medicine: bridging the gap with the neuropsychiatric fluctuation scale Schmitt, Emmanuelle Debu, Bettina Castrioto, Anna Kistner, Andrea Fraix, Valerie Bouvard, Martine Moro, Elena Front Neurol Neurology BACKGROUND: Neuropsychiatric fluctuations (NpsyF) are frequent and disabling in people with Parkinson’s disease (PD). In OFF-medication, NpsyF entail minus neuropsychiatric symptoms (NPS) like anxiety, apathy, sadness, and fatigue. In ON-medication, NpsyF consist in plus NPS, such as high mood, hypomania, and hyperactivity. Accurate identification of these NpsyF is essential to optimize the overall PD management. Due to lack of punctual scales, the neuropsychiatric fluctuation scale (NFS) has been recently designed to assess NpsyF in real time. The NFS comprises 20 items with two subscores for plus and minus NPS, and a total score. OBJECTIVE: To evaluate the psychometric properties of the NFS in PD. METHODS: PD patients with motor fluctuations and healthy controls (HC) were assessed. In PD patients, the NFS was administrated in both the ON-and OFF-medication conditions, together with the movement disorders society-unified Parkinson disease rating scale parts I–IV. Depression (Beck depression scale II), apathy (Starkstein apathy scale) and non-motor fluctuations items of the Ardouin scale of behaviour in PD (ASBPD OFF and ON items) were also assessed. NFS internal structure was evaluated with principal component analysis consistency (PCA) in both medication conditions in PD patients and before emotional induction in HC. NFS internal consistency was assessed using Cronbach’s alpha coefficient. NFS convergent and divergent validity was measured through correlations with BDI-II, Starktein, and ASBPD OFF and ON non motor items. Specificity was assessed comparing NFS global score between the HC and PD populations. Sensitivity was evaluated with t-student test comparing the ON-and the OFF-medication conditions for NFS global score and for minus and plus subscores. RESULTS: In total, 101 consecutive PD patients and 181 HC were included. In PD patients and HC, PCA highlighted one component that explained 32–35 and 42% of the variance, respectively. Internal consistency was good for both the NFS-plus (alpha =0.88) and NFS-minus items (alpha =0.8). The NFS showed a good specifity for PD (p < 0.0001) and a good sensitivity to the medication condition (p < 0.0001). CONCLUSION: The satisfactory properties of the NFS support its use to assess acute neuropsychiatric fluctuations in PD patients, adding to available tools. Frontiers Media S.A. 2023-08-17 /pmc/articles/PMC10469620/ /pubmed/37662035 http://dx.doi.org/10.3389/fneur.2023.1242484 Text en Copyright © 2023 Schmitt, Debu, Castrioto, Kistner, Fraix, Bouvard and Moro. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Schmitt, Emmanuelle
Debu, Bettina
Castrioto, Anna
Kistner, Andrea
Fraix, Valerie
Bouvard, Martine
Moro, Elena
Fluctuations in Parkinson’s disease and personalized medicine: bridging the gap with the neuropsychiatric fluctuation scale
title Fluctuations in Parkinson’s disease and personalized medicine: bridging the gap with the neuropsychiatric fluctuation scale
title_full Fluctuations in Parkinson’s disease and personalized medicine: bridging the gap with the neuropsychiatric fluctuation scale
title_fullStr Fluctuations in Parkinson’s disease and personalized medicine: bridging the gap with the neuropsychiatric fluctuation scale
title_full_unstemmed Fluctuations in Parkinson’s disease and personalized medicine: bridging the gap with the neuropsychiatric fluctuation scale
title_short Fluctuations in Parkinson’s disease and personalized medicine: bridging the gap with the neuropsychiatric fluctuation scale
title_sort fluctuations in parkinson’s disease and personalized medicine: bridging the gap with the neuropsychiatric fluctuation scale
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469620/
https://www.ncbi.nlm.nih.gov/pubmed/37662035
http://dx.doi.org/10.3389/fneur.2023.1242484
work_keys_str_mv AT schmittemmanuelle fluctuationsinparkinsonsdiseaseandpersonalizedmedicinebridgingthegapwiththeneuropsychiatricfluctuationscale
AT debubettina fluctuationsinparkinsonsdiseaseandpersonalizedmedicinebridgingthegapwiththeneuropsychiatricfluctuationscale
AT castriotoanna fluctuationsinparkinsonsdiseaseandpersonalizedmedicinebridgingthegapwiththeneuropsychiatricfluctuationscale
AT kistnerandrea fluctuationsinparkinsonsdiseaseandpersonalizedmedicinebridgingthegapwiththeneuropsychiatricfluctuationscale
AT fraixvalerie fluctuationsinparkinsonsdiseaseandpersonalizedmedicinebridgingthegapwiththeneuropsychiatricfluctuationscale
AT bouvardmartine fluctuationsinparkinsonsdiseaseandpersonalizedmedicinebridgingthegapwiththeneuropsychiatricfluctuationscale
AT moroelena fluctuationsinparkinsonsdiseaseandpersonalizedmedicinebridgingthegapwiththeneuropsychiatricfluctuationscale